Biologic therapy for lymphoma

Current Opinion in Oncology

Volumn 11, Issue 5, 1999, Pages 343-350

  Bendandi, Maurizio ^a   Longo, Dan L ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 2; IODINE 131; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VACCINE; VINCRISTINE; YTTRIUM 90;

ALLOGRAFT; GENE THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; INTERFERONS; LYMPHOMA;

EID: 0032842976     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199909000-00005     Document Type: Review

References (39)

1. Arranz R, Garcia-Alfonso P, Sobrino P, et al.: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998, 16:1538-1546. Like most studies involving interferon, this one shows a modest delay in disease progression but no important influence on patient survival.
2. Solal-Celigny P, Lepage E, Brousse N, et al.: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas; final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998, 16:2332-2338. This positive study suggests that the addition of interferon to doxorubicin-containing chemotherapy in patients with follicular lymphoma and poor risk factors may result in a significant improvement in survival.
3. Cole BF, Solal-Celigny P, Gelber RD, et al.: Quality-of life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998, 16:2339-2344.
4. Longo DL: Interferon toxicity worse in retrospect: impact on Q-TWiST? Quality-adjusted time without symptoms or toxicity. J Clin Oncol 1998, 16:3716-3718.
5. Weiss R, Huhn D, Mitrou P, et al.: HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha2b/zidovudine maintenance therapy. Leuk Lymphoma 1998, 29:103-118.
6. Stadler R, Otte HG, Luger T, et al.: Prospective randomized multicenter clinical trial on the use of interferon-alpha2a plus acitretin versus interferon-alpha2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92:3578-3581. Interferon seems to augment the antitumor effects of PUVA in patients with cutaneous T-cell lymphoma; the interferon plus retinoid was toxic and not an effective combination.
7. Aviles A, Diaz-Maqueo JC, Talavera A, et al.: Maintenance therapy with interferon alfa 2b in Hodgkin's disease. Leuk Lymphoma 1998, 30:651-656.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833. The antibody has substantial single agent activity in indolent lymphoma with responses lasting approximately 1 year.
9. Nguyen DT, Amess JA, Doughty H, et al.: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999, 62:76-82.
10. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932. The antibody also has significant antitumor activity in the setting of aggressive histology B-cell lymphoma and is a candidate for novel combinations with chemotherapy.
11. Tobinai K, Kobayashi Y, Narabayashi M, et al.: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998, 9:527-534.
12. Berinstein NL, Grillo-Lopez AJ, White CA, et al.: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
13. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276. The first report of combining rituximab with chemotherapy; a large fraction of patients with circulating tumor cells cleared those cells from the blood with this therapy.
14. Tetreault S, Abler SL, Robbins B, Saven A: Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol 1998, 16:1635-1637.
15. Micallef IN. Kirk A, Norton A, et al.: Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. Blood 1999, 93:2427-2428.
16. Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999, 5:611-615.
17. Davis TA, Maloney DG, Czerwinski DK, et al.: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998, 92:1184-1190.
18. Hartmann F, Renner C, Jung W, Pfreundschuh M: Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma 1998, 31:385-392.
19. Scadden DT, Scheinkein DP, Bernstein Z, et al.: Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer 1998, 83:2580-2587.
20. McCormick AA, Kumagai MH, Hanley K, et al.: Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999, 96:703-708.
21. King CA, Spellerberg MB, Zhu D, et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281-1286.
22. Wen YJ, Lim SH: In vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998, 103:663-668.
23. Berger CL, Longley BJ, Imaeda S, et al.: Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998, 76:304-311.
24. Liu HM, Newbrough SE, Bhatia SK, et al.: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:3730-3736.
25. Simova J, Bubenik J, Jandlova T, Indrova M: Irradiated IL-2 gene modified plasmacytoma vaccines are more efficient than live vaccines. Int J Oncol 1998, 12:1195-1198.
26. Bendandi M, Gocke C, Kobrin C, et al.: Molecular complete remissions induced by patient-specific vaccination in most patients with follicular lymphoma [abstract]. Blood 1998, 92(suppl 1):153. The administration of idiotype protein with GM-CSF as adjuvant elicits tumor-specific T-cell responses in most patients. Many with PCR-positive cells in the peripheral blood become PCR negative after vaccination.
27. Li PK, Tsang K, Szeto CC, et al.: Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte (sic) activated killer cell therapy. Am J Kidney Dis 1998, 32:813-819.
28. Curti BD, Ochoa AC, Powers GC, et al.: Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol 1998, 16:2752-2760. Autologous anti-CD3-activated CD4+ T cells can traffic to tumor sites in vivo and mediate antitumor effects. Of 4 lymphoma patients on this study, 3 had tumor regressions, one of which was complete.
29. Lokhorst HM, Liebowitz D: Adoptive T-cell therapy. Semin Hematol 1999, 36(suppl 3):26-29. The use of T cells activated with anti-CD3 and anti-CD28 following autologous bone marrow transplantation in patients with refractory lymphoma resulted in complete responses, some of which are durable.
30. Rooney CM, Roskrow MA, Suzuki N, et al.: Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 1998, 9(suppl5):129-132.
31. Khouri IF, Keating M, Korbling M. et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as a treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824. Innovative approach to allogeneic transplantation in which preparative therapy is targeted to remove host T cells rather than to ablate the bone marrow; donor lymphocyte infusions are able to be given without serious GVHD, but the graft-versus-tumor effect seems to be strong.
32. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
33. Or R, Ackerstein A, Nagler A, et al.: Allogeneic cell-mediate and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. J Immunother 1998, 21:447-453.
34. Rooney CM, Smith CA, Ng CY, et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
35. Arguello F, Alexander M, Sterry JA, et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998, 91:2482-2490.
36. Senderowicz AM, Headlee D, Stinson SF, et al.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998, 16:2986-2999.
37. Kenney S, Ge JO, Westphal EM, Olsen J: Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum Gene Ther 1998, 9:1131-1141.
38. Fernandez NC, Levraud JP, Haddada H, Perricaudet M, Kourilsky P: High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 1999, 162:609-617.
39. Tormo M, Tari AM, McDonnell TJ, et al.: Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 down-regulation. Leuk Lymphoma 1998, 30:367-379.